Insights from EHA 2025 – Peter Löffelhardt shares a message of hope

📍 Milan, June 12–15, 2025

Peter Löffelhardt, Founder and CEO of the Global MPN Scientific Foundation, attended the European Hematology Association (EHA) Congress 2025 to connect with researchers, pharmaceutical companies, and patient advocates from around the world.

In his words:

“There’s real momentum in the MPN field. While no new treatments are expected in the next two years, promising therapies are in the pipeline, and early results look encouraging.”

Peter also emphasized the long-term vision:

“Many new molecules are still in early phases, but the industry is committed to symptom control, disease modification — and eventually, a cure.”

🎥 Watch the full video message!

At the Global MPN Scientific Foundation, we believe in staying close to the most relevant updates in the field of hematology. Events like EHA 2025 are a reminder that the MPN landscape is evolving, with new treatments, clinical trials, and international collaboration pushing the boundaries of what’s possible.

Innovation is coming, even if it takes time. We remain committed to transparency, education, and support for our entire MPN community.

🌐 Stay connected via mpnworld.org